SCHEMBL8551555

SCHEMBL8551555

CCOC(=O)CCNC(=O)c1cnco1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
MLYCD O95822 1/20 0.42
ACACB O00763 2/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.39
NAMPT P43490 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
TOP2A P11388 1/20 0.39
PTPN7 P35236 1/20 0.38
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5199877 0.81 POLB (0.53) CYP1A2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL23799182 0.78 HRH3 (0.39) SMN1; SMN2ALDH1A1ACACBMEN1KMT2A
SCHEMBL17725298 0.77 ACACB (0.43) HPGDACACBPOLBHRH3DGAT2
SCHEMBL3827774 0.76 TBXAS1 (0.43) CYP1A2CYP3A4CYP2C19SMN1; SMN2KDM4E
SCHEMBL12999414 0.76 POLB (0.45) CYP1A2CYP3A4CYP2C19SMN1; SMN2KDM4E
SCHEMBL18896237 0.75 NAAA (0.54) SMN1; SMN2KDM4EALDH1A1HPGDMLYCD
SCHEMBL8532598 0.74 POLB (0.54) CYP1A2CYP3A4CYP2C19SMN1; SMN2KDM4E
SCHEMBL414791 0.74 NAMPT (0.46) CYP1A2CYP3A4CYP2C19ALDH1A1ACACB
SCHEMBL23303452 0.72 NAAA (0.57) CYP1A2CYP3A4CYP2C19SMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL29099329 0.72 NAMPT (0.45) CYP1A2CYP2C19ALDH1A1ACACBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012065958-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-24 WO disclosed